References
- Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109
- Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72: 78–89
- Boon AP, O'Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991; 44: 452–454
- Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201
- Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993; 14: 131–139
- Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 1995; 38: 111–117
- Marichal P, Vanden Bossche H. Mechanisms of resistance to azole antifungals. Acta Biochim Pol 1995; 42: 509–516
- Katiyar SK, Edlind TD. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001; 39: 109–116
- P Murray, Baron, E, Pfaller, M, Tenover, F, Yolken, R ( eds). Manual of Clinical Microbiology. Washington: ASM Press; 1999.
- Harry JB, Oliver BG, Song JL, et al. Drug-induced regulation of the MDR1 promoter in Candida albicans. Antimicrob Agents Chemother 2005; 49: 2785–2792
- Prudencio C. SF, Sousa MJ., Corte-Real M., Leao C. Rapid detection of efflux pumps and their relation with drug resistance in yeast cells. Cytometry 2000; 39: 26–35
- Lamb DC CA, Baldwin BC, Kwon-Chung J, Kelly SL. Resistant P450A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett 1995; 368: 326–330
- Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393–400
- Sanglard DBJ. Current understanding of the mode of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. Candida and Candidiasis, R. Calderone. ASM Press, Washington 2002; 349–383
- Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42: 2645–2649
- Hitchcock CA. Resistance of Candida albicans to antifungal agents. Biochem Soc Trans 1993; 41: 1039–1047
- Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol 1986; 132: 2421–2431
- Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 1996; 40: 2443–2446
- Clark FS, Parkinson T, Hitchcock CA, Gow NA. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419–425